Ueno, Makoto http://orcid.org/0000-0003-4480-0029
Morizane, Chigusa
Okusaka, Takuji
Mizusawa, Junki
Kataoka, Tomoko
Ikeda, Masafumi
Ozaka, Masato
Okano, Naohiro
Sugimori, Kazuya
Todaka, Akiko
Shimizu, Satoshi
Mizuno, Nobumasa
Yamamoto, Tomohisa
Sano, Keiji
Tobimatsu, Kazutoshi
Katanuma, Akio
Miyamoto, Atsushi
Yamaguchi, Hironori
Nishina, Tomohiro
Shirakawa, Hirofumi
Kojima, Yasushi
Oono, Takamasa
Kawamoto, Yasuyuki
Furukawa, Masayuki
Iwai, Tomohisa
Sudo, Kentaro
Miyakawa, Hiroyuki
Yamashita, Tatsuya
Yasuda, Ichirou
Takahashi, Hidenori
Kato, Naoya
Shioji, Kazuhiko
Shimizu, Kyoko
Nakagohri, Toshio
Kamata, Ken
Ishii, Hiroshi
Furuse, Junji
,
Funding for this research was provided by:
National Cancer Center Research and Development Fund (grant numbers 23-A-22, 26-A-4, 29-A-3, 2020-J-3)
Japan Agency for Medical Research and Development (grant numbers JP16ck0106079, JP19ck0106350)
Ministry of Health, Labour and Welfare of Japan (Grant-in-Aid for Clinical Cancer Research (H22-ganrinsho-ippan-013))
Article History
Received: 18 February 2021
Accepted: 7 June 2021
First Online: 18 June 2021
Competing interests
: Dr. Ueno reports grants and personal fees from Yakult Honsha, grants and personal fees from Taiho Pharmaceutical, AstraZeneca, Merck Serono, MSD, Daiichi Sankyo and Ono Pharmaceutical, personal fees from Nihon Servier, grants from Astellas Pharma, Eisai, Sumitomo Dainippon Pharma and Incyte. Dr. Morizane reports grants and personal fees from Yakult Honsha, J-Pharma, AstraZeneca, MSD and Taiho Pharmaceutical, grants from Eisai, Merck Biopharma and Ono Pharmaceutical, personal fees from Teijin Pharma, Novartis and Abbvie. Dr. Okusaka reports grants and personal fees from Eli Lilly, Taiho Pharmaceutical, Pfizer Japan and Yakult Honsha, personal fees from Meiji Seika Pharma, grants and personal fees from Ono Pharmaceutical, Eisai, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, Bayer Yakuhin, Chugai Pharmaceutical, Zeria Pharmaceutical, Daiichi Sankyo and MSD, grants from Kyowa Hakko Kirin, NanoCarrier and Baxter, personal fees from EA Pharma, FUJIFILM RI Pharma, Celgene, Teijin Pharma, Shire, AbbVie, Takeda Pharmaceutical, Mundipharma, Nihon Servier and Nippon Shinyaku. Mr. Mizusawa reports grants from the Ministry of Health, Labour and Welfare, Japan and Japan Agency for Medical Research and Development (AMED), personal fees from Chugai Pharmaceutical. Dr. Ikeda reports grants from Yakult Honsha, Ono Pharmaceutical, AstraZeneca, J-Pharma, Merck Serono, Bristol-Myers Squibb, Pfizer, Takeda Pharmaceutical and Chiome Bioscience, personal fees and grants from ASLAN, Nihon Servier, NanoCarrier, Novartis, Bayer Yakuhin, Eli Lilly, MSD and Chugai Pharmaceutical, personal fees from Taiho Phamaceutical, Sumitomo Dainippon Pharma, Teijin Pharma, Mylan, Astellas Pharma, EA Pharma, Shire, Gilead and Otsuka. Dr. Okano reports personal fees from Taiho Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, J-Pharma, Ono Pharmaceutical, Takeda Pharmaceutical and Merck BioPharma. Dr. Shimizu reports grants from Sumitomo Dainippon Pharma, Yakult Honsha, Incyte and AstraZeneca. Dr. Mizuno reports grants and personal fees from Taiho Pharmaceutical, grants from the Ministry of Health, Labour and Welfare, Japan, grants and personal fees from Novartis, AstraZeneca, MSD and Yakult Honsha, grants from NanoCarrier, Eisai, Sumitomo Dainippon Pharma, ASLAN Pharmaceuticals, Incyte and Ono Pharmaceutical, personal fees from Teijin Pharma. Dr. Takahashi reports grants from Taiho Pharmaceutical. Dr. Ishii reports personal fees from Ono Pharmaceutical, Yakult Honsha, Taiho Pharmaceutical, Eli Lilly Japan and Teijin Pharma. Dr. Furuse reports grants from the National Cancer Center Research and Development Fund and a Grant-in-Aid for Clinical Cancer Research from the Ministry of Health, Labour and Welfare of Japan, personal fees from Eisai, Bayer Yakuhin, Taiho Pharmaceutical, Ono Pharmaceutical, Novartis, Yakult Honsha, Teijin pharma, Shionogi, EA Pharma, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Mochida Pharmaceutical, Nihon Servier, Sanofi, Fujifilm Toyama Chemical, Nobelpharma, Pfizer, Sawai Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Merck Serono, Nippon Kayaku, MSD, Shire and Kyowa Hakko Kirin, grants from Ono Pharmaceutical, MSD, Sumitomo Dainippon Pharma, J-Pharma, Yakult Honsha, AstraZeneca, Daiichi Sankyo, Eisai, Bayer Yakuhin, Pfizer, NanoCarrier, Kyowa Hakko Kirin, Taiho Pharmaceutical, Chugai Pharmaceutical, Sanofi, Takeda Pharmaceutical, Mochida Pharmaceutical, Astellas Pharma and Eli Lilly Japan. All other authors declare no conflicts of interest in relation to the present work.